June 12, 2024

Ensem Therapeutics Announces Achievement of Milestone Following Entry of Small Molecule CDK2 Inhibitor into Clinical Trials for Solid Tumors

January 3, 2024

ENSEM Expands its Leadership Team with the Appointment of Jeff Kutok, M.D., Ph.D. as Chief Scientific Officer

November 21, 2023

BeiGene stakes out space in hot cancer niche, offering up $1.3B in biobucks for preclinical prospect

November 21, 2023

BeiGene and Ensem Therapeutics Announce Partnership to Advance Differentiated CDK2 Inhibitor

June 5, 2023

ENSEM Announces the Promotion of Shengfang Jin, PhD to President & Chief Executive Officer

April 7, 2022

With an eye to ‘non-obvious binding sites,’ CBC Group launches precision medicine play with $67M and ex-Editas exec at the helm

April 6, 2022

Ensem Therapeutics, a CBC Group-Incubated Biopharma Company, Raises $67 Million in Series A Financing to Develop Small Molecule Medicines for Difficult-to-Drug Targets